Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DARE Stock Forecast 2026-2027
$1.98
Current Price
$29.66M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DARE Price Targets
+506.1%
To High Target of $12.00
+354.5%
To Median Target of $9.00
+304.0%
To Low Target of $8.00
DARE Price Momentum
+3.1%
1 Week Change
-8.8%
1 Month Change
-33.3%
1 Year Change
+2.6%
Year-to-Date Change
-78.5%
From 52W High of $9.19
+55.9%
From 52W Low of $1.27
📊 TOP ANALYST CALLS
Did DARE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Dare Bioscience is one of their latest high-conviction picks.
Latest DARE Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, DARE has a bullish consensus with a median price target of $9.00 (ranging from $8.00 to $12.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.98, the median forecast implies a 354.5% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 506.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DARE Analyst Ratings
3
Buy
0
Hold
0
Sell
DARE Price Target Range
Low
$8.00
Average
$9.00
High
$12.00
Current: $1.98
Latest DARE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DARE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $12.00 |
| Sep 4, 2025 | Maxim Group | Buy | Upgrade | $N/A | |
| Apr 1, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 16, 2024 | Jones Trading | Buy | Maintains | $N/A | |
| Aug 14, 2024 | Maxim Group | Hold | Downgrade | $N/A | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 15, 2024 | Brookline Capital | Buy | Upgrade | $N/A | |
| May 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 17, 2024 | Brookline Capital | Hold | Downgrade | $N/A | |
| Apr 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 10, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 11, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 13, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 6, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 22, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 12, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 31, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Dare Bioscience Inc. (DARE) Competitors
The following stocks are similar to Dare Bioscience based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DARE
Dare Bioscience
mkt cap
30.26M
Dare Bioscience Inc. (DARE) Financial Data
Dare Bioscience Inc. has a market capitalization of $29.66M with a P/E ratio of 0.1x. The company generates $1.16M in trailing twelve-month revenue with a 71.3% profit margin.
Revenue growth is +499.6% quarter-over-quarter, while maintaining an operating margin of -1,967.1% and return on equity of -471.4%.
Valuation Metrics
Market Cap
$29.66M
Enterprise Value
$18.92M
P/E Ratio
0.1x
PEG Ratio
0.0x
Price/Sales
26.1x
Growth & Margins
Revenue Growth (YoY)
+499.6%
Gross Margin
-58.9%
Operating Margin
-1,967.1%
Net Margin
+71.3%
EPS Growth
+499.6%
Financial Health
Cash/Price Ratio
+62.4%
Current Ratio
1.0x
Debt/Equity
978.0x
ROE
-471.4%
ROA
-32.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Dare Bioscience Inc. (DARE) Business Model
About Dare Bioscience Inc.
What They Do
Develops pharmaceuticals for women's reproductive health.
Business Model
The company focuses on the development and commercialization of differentiated therapies in women's reproductive health. It makes money by advancing its product portfolio, which includes key offerings like Ovaprene and Topical Sildenafil, aimed at addressing unmet needs in contraception and female sexual dysfunction.
Additional Information
Dare Bioscience Inc. is a clinical-stage biopharmaceutical company founded in 2005 and is headquartered in San Diego, California. The company operates within the health technology sector, specifically targeting innovative solutions that enhance women's health and well-being.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
21
CEO
Ms. Sabrina Martucci Johnson
Country
United States
IPO Year
2014
Website
darebioscience.comDare Bioscience Inc. (DARE) Latest News & Analysis
Latest News
Quick Summary
Daré Bioscience received a $1 million award from NIAID, bringing total NIH funding for its DARE-HPV project to $2 million. This supports Phase 2 trials for a treatment addressing high-risk HPV.
Why It Matters
Daré Bioscience's receipt of $1 million in NIH funding boosts its credibility and financial stability, advancing its Phase 2 study of DARE-HPV, which addresses a significant unmet need in women's health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Daré Bioscience initiated a Phase 2 study for DARE-HPV, a treatment for high-risk HPV infections, backed by a $10M government contract. Data expected in 2027.
Why It Matters
The development of DARE-HPV addresses a significant unmet medical need, with potential market opportunities in women's health. Successful results could boost Daré Bioscience's valuation and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Daré Bioscience, Inc. (DARE) held its Q1 2026 earnings call, discussing financial performance and company updates. Further details can be found in the full transcript.
Why It Matters
The Q1 2026 earnings call provides insights into Daré Bioscience's financial performance, growth prospects, and strategic direction, which can influence stock valuation and investor decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
1 month ago
Quick Summary
A company reported a second positive DSMB review of interim data from the Ovaprene® Phase 3 trial. The Flora Sync LF5™ is set for commercial launch in summer 2026, with revenue expected in June 2026.
Why It Matters
Positive interim data from Ovaprene® may signal strong future sales and growth potential, while anticipated product launches could enhance revenue streams, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dare Bioscience, Inc. (NASDAQ:DARE) shares rose after the company reported positive interim results from its Phase 3 trial for Ovaprene, a hormone-free contraceptive.
Why It Matters
Positive interim results from Dare Bioscience's Phase 3 trial for Ovaprene could signal strong market potential, increasing investor confidence and potentially driving share prices higher.
Source: Benzinga
Market Sentiment:
Positive
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
1 month ago
Quick Summary
Daré Bioscience reported positive interim results from its Phase 3 trial for Ovaprene, a first-in-category, hormone-free monthly contraceptive, with continued support from the DSMB.
Why It Matters
Positive interim results and continued study support for Ovaprene may enhance Daré Bioscience's market position, potentially driving stock value and attracting investor interest in women's health innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DARE Stock
What is Dare Bioscience Inc.'s (DARE) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Dare Bioscience Inc. (DARE) has a median price target of $9.00. The highest price target is $12.00 and the lowest is $8.00.
Is DARE stock a good investment in 2026?
According to current analyst ratings, DARE has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DARE stock?
Wall Street analysts predict DARE stock could reach $9.00 in the next 12 months. This represents a 354.5% increase from the current price of $1.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dare Bioscience Inc.'s business model?
The company focuses on the development and commercialization of differentiated therapies in women's reproductive health. It makes money by advancing its product portfolio, which includes key offerings like Ovaprene and Topical Sildenafil, aimed at addressing unmet needs in contraception and female sexual dysfunction.
What is the highest forecasted price for DARE Dare Bioscience Inc.?
The highest price target for DARE is $12.00 from Douglas Tsao at HC Wainwright & Co., which represents a 506.1% increase from the current price of $1.98.
What is the lowest forecasted price for DARE Dare Bioscience Inc.?
The lowest price target for DARE is $8.00 from at , which represents a 304.0% increase from the current price of $1.98.
What is the overall DARE consensus from analysts for Dare Bioscience Inc.?
The overall analyst consensus for DARE is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $9.00.
How accurate are DARE stock price projections?
Stock price projections, including those for Dare Bioscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 4:19 AM UTC